If your doctor has talked to you about cholesterol before, the conversation may sound a little different next time.
The newest cholesterol guidelines shift the focus from simply treating high cholesterol as a number to preventing heart disease much earlier.
Not all endometrial cancers behave the same way. Some tumors are treated successfully and never return, while others come back despite appearing low-risk when first diagnosed. This has led researchers to look beyond traditional pathology and focus on the genetic changes that may influence how a cancer behaves.
One gene receiving increasing attention is CTNNB1. Recent research suggests that mutations in this gene may help identify patients who face a higher risk of recurrence, even when their cancer appears less aggressive under a microscope. As precision medicine continues to advance, CTNNB1 could become an important tool for improving treatment decisions and patient outcomes.
The U.S. Food and Drug Administration recently cleared for marketing the first over-the-counter (OTC) continuous glucose monitor (CGM) for children, Dexcom Inc.’s Stelo Glucose Biosensor System, an integrated CGM (iCGM) indicated for people two years of age and older who do not use insulin. The FDA previously cleared the Stelo Glucose Biosensor System OTC for individuals 18 years and older in March 2024.
Health officials are investigating a multistate increase in cyclosporiasis, an intestinal illness caused by the parasite Cyclospora cayetanensis. Recent cases have been reported in multiple states, and investigators are working to identify the food source responsible for the outbreak. Because the parasite is often linked to fresh produce, outbreaks can affect people across several regions before the source is identified.
The American Heart Association’s updated cholesterol guidance reflects these advances. Rather than focusing on cholesterol numbers alone, the recommendations place greater emphasis on a person’s overall cardiovascular risk, earlier prevention, and using the right treatment for the right patient. The goal is to identify people who can benefit from treatment before they experience a heart attack or stroke.
Prostate cancer is one of the most common cancers affecting men worldwide. In many cases, it grows slowly and may not cause symptoms for years. However, some forms can be aggressive and spread beyond the prostate, making early detection and appropriate treatment extremely important.
Researchers continue to learn more about the genetic and biological factors that drive prostate cancer, leading to improved screening methods and more personalized treatment options. A comprehensive review of prostate cancer research highlights how advances in genetics, diagnosis, and treatment are helping improve outcomes while reducing unnecessary treatment for low-risk disease.